PCN83 A COST-EFFECTIVENESS ANALYSIS (CEA) FOR DENOSUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY FOR CANCER TREATMENTINDUCED BONE LOSS (CTIBL) IN NON-METASTATIC PROSTATE CANCER (PRCA)- A SWEDISH PERSPECTIVE
Abstract
Authors
S Shroff M Martin M Kearney M Lothgren A Bracco